Please select the eligibility criteria that correspond to the clinical trial below.
Title: Transepithelial Corneal Collagen Crosslinking for Keratoconus and Corneal Ectasia
Brief Summary: Corneal collagen crosslinking (CXL) has been proposed as an effective method of reducing progression of both keratoconus and corneal ectasia after surgery, as well as possibly decreasing the steepness of the cornea in these pathologies. During previous studies of the CXL procedure, the surface epithelial cells have been removed. Transepithelial crosslinking in which the epithelium is not removed has been proposed to offer a number of advantages over traditional crosslinking including an increased safety profile by reducing the risk for infection as no epithelial barrier will be broken, faster visual recovery and improved patient comfort in the early postoperative healing period.


Options:
A: Inclusion Criteria:

* diagnosis of infectious keratitis

Exclusion Criteria:

* corneal ulcer that has perforated
* corneal ulcer that has produced a descemetocele
* women who are pregnant or breastfeeding
* patients who are immunocompromised or unwilling or unable to comply with a medication regimen
B: Inclusion Criteria:

* 18 years of age or older
* A diagnosis of keratoconus or a diagnosis of corneal ectasia after corneal refractive surgery
* Vision with contact lenses or glasses is worse than 20/20
* Corneal thickness greater than 375 microns at the thinnest point

Exclusion Criteria:

* Eyes classified as either normal, atypical normal, or keratoconus suspect on the severity grading scheme.
* Corneal pachymetry ≤ 350 microns at the thinnest point measured by Pentacam in the eye(s) to be treated.
* Previous ocular condition (other than refractive error) in the eye(s) to be treated that may predispose the eye for future complications
* Clinically significant corneal scarring in the CXL treatment zone
* Pregnancy (including plan to become pregnant) or lactation during the course of the study
* A known sensitivity to study medications
* Patients with nystagmus or any other condition that would prevent a steady gaze during the CXL treatment or other diagnostic tests.
* Patients with a current condition that, in the investigator's opinion, would interfere with or prolong epithelial healing.
C: Inclusion Criteria:

* Evidence of corneal ulcer grade II or III (bacteria or fungal, or presumed bacterial or fungal)
* Age more than 6 year
* Patients can understand and can follow the study protocol

Exclusion Criteria:

* Pregnancy by history or urine test
* Evidence of herpetic keratitis
* Evidence of corneal perforation
* Evidence of autoimmune disease
* Known allergy to study medication
D: Inclusion Criteria:

* Infectious bacterial or fungal keratitis with : size \> 2mm or within the central corneal area ( 3mm of the visual axis ) or with a reaction in anterior chamber.
* Being major responsible.
* Agreement in writing to participate in the study.
* Being affiliated to a national insurance scheme.

Exclusion Criteria:

* Present an infectious keratitis without all the previous criteria.
* Herpes or acanthamoeba keratitis
* preperforated or perforated cornea.

General criteria:

* Pregnant woman.
* Minors(miners).
* Adults under guardianship.
* Patient can not be followed during 3 necessary months.
* French speaking patient.
* Unaffiliated patient in a national insurance scheme.
* HIV infected patients

Answer: B